Actively Recruiting
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
Led by Shengjing Hospital · Updated on 2026-02-09
100
Participants Needed
1
Research Sites
224 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.
CONDITIONS
Official Title
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years old
- Confirmed cirrhosis by laboratory, imaging, and clinical symptoms
- Have had 3D-MRE and 2D-MRE scans within 1 month before HVPG measurement
- Provided written informed consent
You will not qualify if you...
- Any previous liver or spleen surgery
- Liver cancer or chronic acute liver failure
- Acute portal hypertension
- Unreliable HVPG, 3D-MRE, or 2D-MRE results due to technical problems
- Received liver interventional therapy between HVPG and MRE
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004
Actively Recruiting
Research Team
Y
Yu Shi
CONTACT
Z
Zhiying Wang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here